Pureos Bioventures to raise new fund in 2022
Pureos Bioventures, a Swiss VC investing in pre-clinical and clinical-stage drug developers, plans to raise a second fund of approximately CHF 250m-300m by the end of next year, managing partner Martin Münchbach told Unquote.
More on Funds
Advent raises USD 25bn for GPE X
Around 40% larger than its predecessor, the new fund was raised in less than six months, managing director Johanna Barr tells Unquote
PEAL Capital buys majority stake in Derma Medical
Deal marks the first investment by the female-led GP’s debut fund, which seeks to raise USD 300m
B4 Investimenti on track for new fund launch in late 2023
Italian GP plans to hit the road for Fund III after the end of its current vehicle’s investment period
DBAG to target EUR 1.3bn-EUR 1.5bn for new buyout fund next year
German GP’s new vehicle will be slightly larger than its predecessor, which is set to complete deployment in two years
Latest News
Perusa to exit Müpro in SBO to IK
Management of the German industrial fixings supplier will reinvest with a minority stake
Ufenau acquires EinzelNet in first deal with Fund VII
Management and founders will retain a 25% stake in the Spanish IT services group; bolt-ons planned under new owner
Advent raises USD 25bn for GPE X
Around 40% larger than its predecessor, the new fund was raised in less than six months, managing director Johanna Barr tells Unquote
MB Funds to exit Raksystems in sale to Trill Impact
New majority owner will seek to expand the Finnish green building services specialist across Europe